万达生物制药 VNDA 深 沪
等待开盘 08-21 09:30:00 美东时间
4.575
+0.045
+0.99%
华盛通- 最 高4.5854
- 今 开4.53
- 成交量 8.74万股
- 最 低 4.525
- 昨 收 4.53
- 总市值 2.70亿
- 52周最高 5.545
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 3.8092
- 委 比 28.14%
- 总股本 5908.91万
- 历史最高 33.44
- 量 比 0.37
- 振 幅 1.33%
- 历史最低 2.92
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vanda Wins Major Court Battle For Jet Lag Drug, Forcing FDA To Revisit Rejection
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its longstanding dispute with the agency regarding the approvability
08-18 19:08
中信证券：首予阜博集团“买入”评级 目标价8港元 看好全球维持版权保护长期需求
中信证券发布研报称，看好阜博集团（03738）投资价值公司，首次覆盖，给予“买入”评级。预计公司2025-2027年收入分别为29.79/37.38/47.1...
08-14 15:07
Vanda Pharmaceuticals Affirms FY2025 Sales Guidance of $210.00M-$250.00M vs $227.72M Est
Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2025 sales outlook from $210.00 million-$250.00 million to $210.00 million-$250.00 million vs $227.72 million estimate.
07-31 19:37
Vanda Pharma Q2 EPS $(0.46) Misses $(0.36) Estimate, Sales $52.59M Miss $54.60M Estimate
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.36) by 28.85 percent. This is a 475 percent decrease over losses of $(0.08) per share from the
07-31 19:36
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
Vanda Pharmaceuticals Q2 Earnings Preview
Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. The consensus EPS Estimate is -$0.36 and the consensus revenue estimate is ...
07-30 23:04
Vanda Pharma Announces First Dose In First-In-Human Clinical Trial To Evaluate Safety And Tolerability Of VCA-894A, ASO Therapeutic, For Patient With Rare Variant In IGHMBP2 Gene Causing Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO)
06-10 20:12
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
WASHINGTON, May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual ...
05-27 21:00
